Home › NDC Lookup › RxCUI directory › RxCUI 201185

Mafenide 85 MG/ML Topical Cream [Sulfamylon] — RxCUI 201185

RxNorm drug concept · Semantic branded drug
RxCUI 201185 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI201185
Official nameMafenide 85 MG/ML Topical Cream [Sulfamylon]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asSulfamylon 8.5 % Topical Cream; Sulfamylon 85 MG/ML Topical Cream
FDA products mapped1
Package NDCs mapped3
Reported Medicaid activity (SDUD)12 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Mafenide 85 MG/ML Topical Cream [Sulfamylon] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Mafenide 85 MG/ML Topical Cream [Sulfamylon] RxCUI 201185

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Mafenide 6572
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Sulfamylon 258054
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mafenide Topical Cream 377749
    • Mafenide Topical Product 1156950
    • Mafenide Topical Cream [Sulfamylon] 380948
    • Sulfamylon Topical Product 1183771
    • Topical Cream 316982
    • Topical Product 1151122
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Mafenide 85 MG/ML Topical Cream SCD · 311406
  • Mafenide 85 MG/ML SCDC · 343194
  • Mafenide Topical Cream SCDF · 377749
  • Mafenide Topical Product SCDG · 1156950

Brand-Name Concepts

  • Mafenide 85 MG/ML [Sulfamylon] SBDC · 565729
  • Mafenide Topical Cream [Sulfamylon] SBDF · 380948
  • Sulfamylon Topical Product SBDG · 1183771
  • Sulfamylon BN · 258054

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 201185 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
16571-0723-12 1 TUBE in 1 CARTON (16571-723-12) / 113.4 g in 1 TUBE SULFAMYLON Rising Pharma Holdings, Inc. 2020-05-18
16571-0723-48 453.6 g in 1 JAR (16571-723-48) SULFAMYLON Rising Pharma Holdings, Inc. 2020-05-18
16571-0723-60 1 TUBE in 1 CARTON (16571-723-60) / 56.7 g in 1 TUBE SULFAMYLON Rising Pharma Holdings, Inc. 2020-05-18
Observed labelers: Rising Pharma Holdings, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per gm · median
$1.2343
Range $1.2343–$1.2343 · middle 50% $1.2343–$1.2343 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.